VALANX Biotech wins Boehringer Ingelheim Innovation Prize

We are proud to announce that we have been chosen as winner of the Boehringer Ingelheim Innovation Prize, awarded for the first time at the MEET2WIN conference in Bordeaux, France. VALANX was chosen for the game-changing potential of its site-specific protein conjugation technology as well as for the promise of its early preclinical pipeline.

Additionally at the conference VALANX Biotech was chosen to present in-depth our technology in front of the MATWIN International Board, a high profile group of industry representatives. Michael Lukesch, CEO comments: This level of interest and appreciation really shows us that we are on the right track. Many thanks to the organizers and juries for their attention and to the VALANX team for making great science possible.”

Michael Lukesch, CEO accepts the prize from the Boehringer Ingelheim Innovation prize jury.


LinkedIn Post VALANX

LinkedIn Post Boehringer Ingelheim